Q-omics provides the consensus-scored LINCMD1 profile across patient tissues and cancer cell-line models. LINCMD1 expression is associated with patient survival in 16 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, LINCMD1 is differentially expressed in 6, with the highest sampling consensus in KIRC. Additionally, LINCMD1 RNA expression shows 10,529 significant protein co-abundance associations, with the highest sampling consensus in HNSC. Together, these results highlight KIRC, and HNSC as cancer lineages where LINCMD1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LINCMD1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LINCMD1 survival associations across molecular data types. LINCMD1 RNA expression shows survival associations in the most cancer types (16). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LINCMD1 RNA expression–survival associations across cancer types. High LINCMD1 expression shows unfavorable associations in MESO, UCEC, LIHC and CESC, but favorable associations in KIRC and KIRP. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for LINCMD1 RNA expression.
This table summarizes LINCMD1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for LINCMD1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LINCMD1 shows lower tumor expression in KICH and BRCA and higher tumor expression in KIRC, KIRP, LUAD and THCA. The KIRC box plot shows higher LINCMD1 RNA expression in tumor versus normal tissue (log2 FC = +0.941, t-test p < 0.001).
This table shows molecular features associated with LINCMD1 in patient tissues and cancer cell lines. In patient samples, LINCMD1 shows the broadest associations at the RNA and protein expression levels, with HNSC recurring as the lineage with the largest associated feature set.
